Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

The availability of such kidney transplants outside of the research setting could substantially improve organ availability ...

The drug has been approved in Europe and the US as a treatment for HIV/AIDS but does not yet have regulatory approval anywhere in the world as an HIV prevention drug. Once approved, producing enough ...

Namibia has made significant strides in stemming the spread of HIV and AIDS through education and prevention. However, for people like Anna Engomba, the arrival of new, life-saving medication cannot ...

To bridge the gap until generic versions become available, Gilead has also committed to supply the product at no profit to the chosen companies until the selected generic manufacturers are able to ...

This decision opens the market for generic versions, promoting affordable access to treatment and potentially ... the first-line HIV drug will likely be available at a fraction of the innovator ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

The first presentation will take place in November 2024 at the HIV Drug Therapy 2024 conference in Glasgow , Scotland. During this event, Code Pharma will unveil promising early-stage results from ...